Addex Therapeutics Ltd.

Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands evidence supporting mGlu7 as a promising therapeutic target for central nervous system disorders, including mood disorders, anxiety, and PTSD. The study showed ADX71743 increased wakefulness and reduced both REM and non-REM sleep in rats, while also altering stress-induced changes in key neurotransmitters.

Addex Therapeutics announced that its shareholders approved all proposals from the Board of Directors at the 2026 Annual General Meeting with a large majority. Key approvals included the 2025 financial statements, compensation report, and compensation for the board and executive management. Shareholders also re-elected all current board members, including Dr. Vincent Lawton as Chairman, and re-appointed BDO SA as auditors. Amendments to the Articles of Association concerning capital structure were also approved.

Addex Therapeutics reported an increased net loss of CHF 1.71 million for Q1 2026, compared to CHF 1.47 million in Q1 2025. The company's cash and cash equivalents significantly decreased to CHF 0.94 million as of March 31, 2026, from CHF 1.64 million at the end of 2025, raising substantial doubt about its ability to continue as a going concern beyond July 2026. Operationally, its spin-out Neurosterix is advancing a Phase 1 study for NTX-253, and Addex continues preclinical development for its GABAB PAM chronic cough candidate.

Addex Therapeutics announced its 2026 Annual General Meeting (AGM) will take place on Monday, June 29, 2026, in Geneva. The agenda includes the approval of the 2025 Annual Report, financial statements, and a consultative vote on the 2025 Compensation Report. Shareholders will also vote on the re-election of the Board of Directors, including Chairman Vincent Lawton, and the re-election of the Auditor. Key proposals include amendments to the Articles of Association to increase the capital band and conditional share capital, and the approval of compensation for the Board and Executive Management.

Addex Therapeutics reported a net loss of CHF 6.7 million for the full year 2025, a significant decrease from a net profit of CHF 7.1 million in 2024, primarily due to the consideration received from the Neurosterix transaction in 2024. The company ended the year with CHF 1.6 million in cash and cash equivalents. Operationally, Addex advanced its GABAB PAM chronic cough candidate, repositioned dipraglurant for brain injury recovery with a new collaboration agreement with Sinntaxis, and regained rights to its mGlu2 PAM asset, ADX71149. Partner Indivior also progressed its GABAB PAM program, and Addex made a strategic investment in Stalicla SA.

Addex Therapeutics Ltd. filed a Form 6-K with the SEC on April 29, 2026. This filing announced the issuance of a press release on the same date, which is attached as Exhibit 99.1 and incorporated by reference into the company's registration statements. The 6-K itself did not detail the content of the press release.